Suven Pharmaceuticals (BOM:543064) EPS (Diluted) : ₹11.81 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals EPS (Diluted)?

Suven Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹2.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹11.81.

Suven Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was ₹2.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹11.81.

Suven Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was ₹2.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹11.81.

During the past 12 months, Suven Pharmaceuticals's average EPS without NRIGrowth Rate was -27.00% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -5.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Suven Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 54.60% per year. The lowest was -5.80% per year. And the median was 9.70% per year.

Suven Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Suven Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals EPS (Diluted) Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EPS (Diluted)

Get a 7-Day Free Trial

12.45

14.23

17.83

16.16

11.80

Suven Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															4.87	4.74	3.13	1.84	2.10

Competitive Comparison of Suven Pharmaceuticals's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suven Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's PE Ratio falls into.

Suven Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Suven Pharmaceuticals's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(3002.806	-	0)	/	254.475
	=	11.80

Suven Pharmaceuticals's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(533.731	-	0)	/	254.269
	=	2.10

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11.81

Suven Pharmaceuticals (BOM:543064) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Suven Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals (BOM:543064) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » EPS (Diluted)

Traded in Other Exchanges

SUVENPHAR:India

Address

3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines